ACE2-IgM-Fc FUSION PROTEINS AND USES THEREOF
US-2024307512-A1 · Sep 19, 2024 · US
Method for prophylaxis and/or treatment of ErbB2 positive cancers
US10155028B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10155028-B2 |
| Application number | US-201414913515-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 20, 2014 |
| Priority date | Aug 26, 2013 |
| Publication date | Dec 18, 2018 |
| Grant date | Dec 18, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are compositions and methods for prophylaxis and/or therapy of ErbB2-positive cancer. The compositions include pharmaceutical preparations that contain isolated or recombinant or modified peptidase D (PEPD) proteins. The methods include prophylaxis and/or therapy of ErbB2-positive cancer by administering a PEPD to an individual who has or is at risk for developing ErbB2-positive cancer.
First claim
Opening claim text (preview).
We claim: 1. A method for therapy of ErbB2-positive cancer in an individual, the method comprising selecting an individual for the therapy based on a determination of ErbB-2 positive cancer cells in a sample of a tumor from the individual, and subsequently inhibiting the growth of the tumor by administering to the individual an effective amount of a composition comprising peptidase D (PEPD) comprising a mutation of glycine at position 278 of SEQ ID NO:1, such that growth of the ErbB2-positive tumor is inhibited. 2. The method of claim 1 , further comprising administering a coagulation inhibitor to the individual. 3. The method of claim 1 , wherein the PEPD is a component of a fusion protein. 4. The method of claim 1 wherein the PEPD is conjugated to a chemotherapeutic agent. 5. The method of claim 1 , wherein the mutation of the glycine at position 278 of SEQ ID NO:1 is a G278D mutation. 6. The method of claim 5 , further comprising administering a coagulation inhibitor to the individual.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antineoplastic agents · CPC title
Exopeptidases (3.4.11-3.4.19) · CPC title
Xaa-Pro dipeptidase (3.4.13.9) i.e. prolidase · CPC title
Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10155028B2 cover?
- Provided are compositions and methods for prophylaxis and/or therapy of ErbB2-positive cancer. The compositions include pharmaceutical preparations that contain isolated or recombinant or modified peptidase D (PEPD) proteins. The methods include prophylaxis and/or therapy of ErbB2-positive cancer by administering a PEPD to an individual who has or is at risk for developing ErbB2-positive cancer.
- Who is the assignee on this patent?
- Health Research Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K38/4813. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).